DALLAS, Dec. 19, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE --  Kali, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) earlier today announced the new Kali Cannabis Therapies subsidiary to develop cannabis biotechnology treatment alternatives to chemical pharmaceuticals.  

Kali-Extracts Releases Preclinical Research Study Results On Therapy For Respiratory Disease Driving $11 Billion Treatment Market

The Kali Cannabis Therapies announcement this morning sheds light on years of preclinical research and development results rendered from experiment with cannabis extracts derived from Kali’s patented cannabis extraction process.  President Trump has indicated his intention to sign the Farm Bill legalizing hemp farming into law tomorrow, Thursday, December 20th, 2018.

“I’ve been conducting research on cannabis therapies for a variety of conditions for years under the shadow cast by outdated and government regulations,” said Frederick Ferri, CEO of Kali-Extracts. “Government policy makers are finally reaching an age of cannabis enlightenment and a clean fresh light is about to shine on all Kali-Extracts work.  I expect the legalization of hemp farming to bring light on the yet unrecognized overall value of medical cannabis market.  I expect Kali-Extract’s cannabis intellectual property to stand out in the crowd.”

To learn more about Kali-Extracts, Inc., visit www.kali-extracts.com

Disclaimer/Safe Harbor: 

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Kali, Inc.
Frederick Ferri
(214) 210-0459